Alkermes (NASDAQ:ALKS) Issues FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus EPS estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Alkermes Stock Performance

Shares of Alkermes stock traded up $0.77 on Wednesday, reaching $32.73. 858,619 shares of the stock were exchanged, compared to its average volume of 1,520,002. Alkermes has a twelve month low of $22.90 and a twelve month high of $33.00. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $5.30 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 1.83 and a beta of 0.49. The business has a 50 day moving average price of $30.16 and a two-hundred day moving average price of $28.65.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. Analysts anticipate that Alkermes will post 2.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALKS. Deutsche Bank Aktiengesellschaft started coverage on shares of Alkermes in a research report on Tuesday. They issued a “buy” rating and a $40.00 target price for the company. Piper Sandler restated an “overweight” rating and issued a $37.00 price target (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. Mizuho raised their target price on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.33.

Insider Activity at Alkermes

In related news, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the transaction, the director now directly owns 23,013 shares in the company, valued at approximately $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Craig C. Hopkinson sold 100,918 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total value of $3,234,421.90. Following the transaction, the executive vice president now directly owns 44,290 shares of the company’s stock, valued at $1,419,494.50. The trade was a 69.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,189 shares of company stock worth $5,723,518. Insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.